Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B

被引：59

作者：

Fensterle, J. ^{[1
,2
]}

Bergmann, B. ^{[1
,3
]}

Yone, C. L. R. P. ^{[1
]}

Hotz, C. ^{[1
]}

Meyer, S. R. ^{[1
]}

Spreng, S. ^{[3
,4
]}

Goebel, W. ^{[3
]}

Rapp, U. R. ^{[1
]}

Gentschev, I. ^{[1
]}

机构：

[1] Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany

[2] AEterna Zentaris GmbH, Frankfurt, Germany

[3] Univ Wurzburg, Dept Microbiol, D-97078 Wurzburg, Germany

[4] Berna Biotech Ltd, Bern, Switzerland

来源：

CANCER GENE THERAPY | 2008年 / 15卷 / 02期

关键词：

bacterial cancer vaccines; prostate-specific antigen; cholera toxin subunit B; hemolysin (HlyA) secretion system ( T1SS); cancer immunotherapy;

D O I：

10.1038/sj.cgt.7701109

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Prostate cancer is the most common malignant tumor in men and is normally associated with increased serum levels of prostate-specific antigen (PSA). Therefore, PSA is one potential target for a prostate cancer vaccine. In this study we analyzed the functionality of new bacterial PSA vaccines, expressed and secreted via the hemolysin (HlyA) secretion system of Escherichia coli, the prototype of Type I secretion systems (T1SS) using an attenuated Salmonella enterica serovar Typhimurium aroA strain as carrier. The data demonstrate that a bacterial live vaccine encompassing T1SS in combination with cholera toxin subunit B can be successfully used for delivery of PSA to induce cytotoxic CD8(+) T-cell responses resulting in an efficient prevention of tumor growth in mice.

引用

页码：85 / 93

页数：9

共 51 条

[1] A plant-based cholera toxin B subunit - insulin fusion protein protects against the development of autoimmune diabetes [J].

Arakawa, T ;

Yu, J ;

Chong, DKX ;

Hough, J ;

Engen, PC ;

Langridge, WHR .

NATURE BIOTECHNOLOGY, 1998, 16 (10) :934-938

[2] A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].

Arlen, PM ;

Gulley, JL ;

Parker, C ;

Skarupa, L ;

Pazdur, M ;

Panicali, D ;

Beetham, P ;

Tsang, KY ;

Grosenbach, DW ;

Feldman, J ;

Steinberg, SM ;

Jones, E ;

Chen, C ;

Marte, J ;

Schlom, J ;

Dahut, W .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269

[3] Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA [J].

Barrou, B ;

Benoît, GR ;

Ouldkaci, M ;

Cussenot, O ;

Salcedo, M ;

Agrawal, S ;

Massicard, SV ;

Bercovici, N ;

Ericson, ML ;

Thiounn, N .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (05) :453-460

[4] Human T cell responses against melanoma [J].

Boon, Thierry ;

Coulie, Pierre G. ;

Van den Eynde, Benoit J. ;

van der Bruggen, Pierre .

ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :175-208

[5] Mechanism of CD1d-restricted natural killer T cell activation during microbial infection [J].

Brigl, M ;

Bry, L ;

Kent, SC ;

Gumperz, JE ;

Brenner, MB .

NATURE IMMUNOLOGY, 2003, 4 (12) :1230-1237

[6] Regulated antigen expression in live recombinant Salmonella enterica serovar typhimurium strongly affects colonization capabilities and specific CD4+-T-cell responses [J].

Bumann, D .

INFECTION AND IMMUNITY, 2001, 69 (12) :7493-7500

[7]

CARDENAS L, 1992, CLIN MICROBIOL REV, V5, P328

[8] One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products [J].

Datsenko, KA ;

Wanner, BL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) :6640-6645

[9] The immunobiology of cancer immunosurveillance and immunoediting [J].

Dunn, GP ;

Old, LJ ;

Schreiber, RD .

IMMUNITY, 2004, 21 (02) :137-148

[10]

Fensterle J, 1999, J IMMUNOL, V163, P4510

← 1 2 3 4 5 6 →